利培酮与奋乃静治疗儿童少年期首发精神分裂症对照研究

The contrast investigation between risperidone and perphenazine in the treatment of first episode of schizophrenia in children and adolescences

目的研究利培酮治疗儿童少年期首发精神分裂症或分裂样精神病的疗效、安全性和不良反应。方法将79例儿童精神分裂症患者随机分为两组,分别用利培酮与奋乃静治疗,疗程12周。以阳性和阴性症状量表(PANSS)评定疗效,副反应量表(TESS)评定不良反应。结果利培酮组和奋乃静组之间疗效无显著性差异,两组治疗后的PANSS总分及各因子分较治疗前均显著下降,利培酮组的不良反应发生率低于奋乃静组。结论利培酮对儿童少年期首发精神分裂症疗效略优于奋乃静,且安全性好,不良反应小。

Objective To explore the efficacy, safety and the main side effects in the treatment of first episode of schizophrenia or schizophreniform disorder in children and adolescences. Methods 79 schizophrenia children were divided into 2 groups. One group was treated with risperidone for 12 weeks, and another perphenazine. PANSS was used to assess the efficacy and TESS was used to assess the main side effects. Results The differences of the efficacy between risperidone and perphenazine weren＇t obvious. The PANSS scores and factor scores of both groups decreased remarkably after the treatment. And the rate of the main side effects of risperidone was lower than that of perphenazine. Conclusions The efficacy of risperidone in the treatment of first episode of schizophrenia in children and adolescences is a little better than that of perphenazine, and it＇s safe and the main side effects are small.